Laurus Labs reports 32.1 percent rise in Q3 profit

Published On 2023-01-31 05:30 GMT   |   Update On 2023-01-31 12:12 GMT
Advertisement

Bengaluru: India's Laurus Labs Ltd reported a 32.1 percent rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines.

The company's consolidated profit rose to 2.03 billion rupees (nearly $25 million) in the three months ended Dec 31, from 1.54 billion rupees a year earlier. Revenue at Laurus Labs, which also makes hepatitis C and oncology drugs, rose more than 50 percent to 15.45 billion rupees.
Advertisement
Laurus Labs said revenue from its Synthesis and active pharmaceutical ingredients (API) businesses, each of which account for more than 40 percent of total revenue, rose 210 percent and 49 percent, respectively, in the latest quarter.
While the Synthesis business manufacturers chemical substances used to make drugs, APIs are key biologically active elements in a drug that help with the desired health effects.

Read also: Laurus Lab gets CDSCO panel nod to Manufacture, Market HIV drug Dolutegravir Sodium Oral Film



Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News